GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » ROC (Joel Greenblatt) %

ProPhase Labs (ProPhase Labs) ROC (Joel Greenblatt) % : -92.26% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ProPhase Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -92.26%.

The historical rank and industry rank for ProPhase Labs's ROC (Joel Greenblatt) % or its related term are showing as below:

PRPH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -101.14   Med: -43.84   Max: 79.12
Current: -48.04

During the past 13 years, ProPhase Labs's highest ROC (Joel Greenblatt) % was 79.12%. The lowest was -101.14%. And the median was -43.84%.

PRPH's ROC (Joel Greenblatt) % is ranked worse than
58.3% of 235 companies
in the Medical Diagnostics & Research industry
Industry Median: -15.21 vs PRPH: -48.04

ProPhase Labs's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


ProPhase Labs ROC (Joel Greenblatt) % Historical Data

The historical data trend for ProPhase Labs's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs ROC (Joel Greenblatt) % Chart

ProPhase Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -72.21 -29.33 44.58 79.12 -50.29

ProPhase Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.20 7.80 -42.17 -53.12 -92.26

Competitive Comparison of ProPhase Labs's ROC (Joel Greenblatt) %

For the Diagnostics & Research subindustry, ProPhase Labs's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs's ROC (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's ROC (Joel Greenblatt) % falls into.



ProPhase Labs ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(38.642 + 5.054 + 2.831) - (9.13 + 2.447 + 2.042)
=32.908

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(40.177 + 3.841 + 2.695) - (15.628 + 2.382 + 0.053999999999998)
=28.649

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of ProPhase Labs for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-44.684/( ( (17.843 + max(32.908, 0)) + (17.47 + max(28.649, 0)) )/ 2 )
=-44.684/( ( 50.751 + 46.119 )/ 2 )
=-44.684/48.435
=-92.26 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProPhase Labs  (NAS:PRPH) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


ProPhase Labs ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136

ProPhase Labs (ProPhase Labs) Headlines

From GuruFocus

ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

By Value_Insider Value_Insider 11-08-2022

ProPhase Labs to Present at Investor Summit Group's Q4 Conference

By GlobeNewswire GlobeNewswire 11-08-2022